Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Guggenheim

Guggenheim began coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research report sent to investors on Monday, MarketBeat.com reports. The brokerage issued a buy rating and a $12.00 price objective on the stock.

Several other equities analysts have also recently weighed in on CMPX. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Leerink Partners lowered Compass Therapeutics from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $5.00 to $4.00 in a report on Friday, November 15th. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, Jefferies Financial Group upped their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, February 10th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.38.

Compass Therapeutics Stock Up 6.5 %

Shares of NASDAQ:CMPX opened at $3.11 on Monday. The firm has a market cap of $427.90 million, a price-to-earnings ratio of -8.41 and a beta of 1.17. Compass Therapeutics has a 12 month low of $0.76 and a 12 month high of $4.08. The company’s fifty day simple moving average is $2.46 and its 200 day simple moving average is $1.90.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CMPX. Rovin Capital UT ADV bought a new stake in Compass Therapeutics in the 3rd quarter valued at $25,000. Intech Investment Management LLC acquired a new position in shares of Compass Therapeutics in the third quarter valued at $30,000. Tower Research Capital LLC TRC raised its position in shares of Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after purchasing an additional 12,917 shares during the period. Independent Advisor Alliance acquired a new stake in shares of Compass Therapeutics during the 4th quarter worth about $26,000. Finally, BNP Paribas Financial Markets bought a new stake in shares of Compass Therapeutics during the 4th quarter worth about $27,000. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.